Order
Press Releases

Market Release of AlphaFlo® Canine Allograft

AlphaFlo-Press-Release-Image

Equus Innovations, a manufacturer of advanced, next-generation veterinary regenerative products, in partnership with AlphaLogix, LLC (Argyle, Texas) announced today successful market release of a new canine allograft, AlphaFlo®.

Read the Press Release
Other Posts

What VEGF and EGF Have to Do With AlphaFlo®

Angiogenesis, the process by which new blood vessels form from existing ones, is an important part of the tissue repair process. Adequate blood supply to tissues is essential for delivering oxygen and nutrients during the repair process, and research into factors that...

How AlphaFlo® Interacts With the Immune System

The immune system plays a central role in how the body responds to tissue injury, infection, and inflammation. Amniotic tissue has been studied for its reported immunomodulatory properties, and AlphaFlo®, as a cryopreserved canine amniotic tissue allograft, contains...

What Makes Amniotic Tissue Anti-Fibrotic? A Closer Look at TIMP-2

Fibrosis, the formation of excess fibrous connective tissue in response to injury or chronic inflammation, is a process that veterinarians encounter across a range of canine cases. Amniotic tissue has been studied for its reported anti-fibrotic properties, and...